文献速递临床试验与 GCP

5-EPIFAT试验方案:一项多中心、随机、安慰剂对照试验,评估哌甲酯、安非他酮、人参和美金刚治疗接受积极治疗的晚期癌症患者疲劳的疗效

5-EPIFAT trial protocol: a multi-center, randomized, placebo-controlled trial of the efficacy of pharmacotherapy for fatigue using methylphenidate, bupropion, ginseng, and amantadine in advanced cancer patients on active treatment.
PubMed 文献 · Trials · 2024-04-03

5-EPIFAT是一项5臂、随机、多盲、安慰剂对照、多中心平行分组试验,计划纳入255例疲劳强度评分≥4分(0-10分)的晚期癌症成人患者,比较哌甲酯、安非他酮、人参、美金刚与安慰剂的疗效与安全性。主要结局为FACIT-F量表评估的癌症相关疲劳随时间变化,次要结局为PRO-CTCAE评估的症状性不良事件,并进行基于决策树的机器学习亚组分析。

要点

  • 5-EPIFAT试验头对头比较哌甲酯、安非他酮、人参、美金刚与安慰剂对晚期癌症患者癌症相关疲劳的疗效。
  • 计划纳入255例疲劳强度评分≥4分(0-10分)的晚期癌症成人患者,干预4周、随访4周。
  • 主要结局为FACIT-F量表评估的疲劳随时间变化,次要结局为PRO-CTCAE评估的症状性不良事件。

核心结论

  • 5-EPIFAT试验结果可能有助于指导临床决策、个体化治疗、未来试验设计以及癌症相关疲劳管理指南的制定。

研究设计与样本

  • 5-EPIFAT研究是一项5臂、随机、多盲、安慰剂对照、多中心试验,采用平行分组设计,等比例分配,比较四种药物(哌甲酯、安非他酮、人参、美金刚)与安慰剂治疗癌症相关疲劳的疗效和安全性。
  • 计划招募255例晚期癌症成人患者,疲劳强度按0-10分评分≥4分。
  • 研究周期包括4周干预和4周随访,随时间重复测量。
  • 主要结局为FACIT-F量表评估的癌症相关疲劳随时间变化水平。
  • 次要结局为PRO-CTCAE评估的症状性不良事件,并采用基于决策树的机器学习算法进行亚组分析,用于同质亚组中不同药物的临床预测。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer-related fatigue (CRF) is still undertreated in most patients, as evidence for pharmacological treatments is limited and conflicting. Also, the efficacy of the pharmacological agents relative to each other is still unclear. Therefore, medications that may potentially contribute to improving CRF will be investigated in this head-to-head trial. Our main objective is to compare the efficacy of methylphenidate vs. bupropion vs. ginseng vs. amantadine vs. placebo in patients with advanced cancer. METHODS: The 5-EPIFAT study is a 5-arm, randomized, multi-blind, placebo-controlled, multicenter trial that will use a parallel-group design with an equal allocation ratio comparing the efficacy and safety of four medications (Methylphenidate vs. Bupropion vs. Ginseng vs. Amantadine) versus placebo for management of CRF. We will recruit 255 adult patients with advanced cancer who experience fatigue intensity ≥ 4 based on a 0-10 scale. The study period includes a 4-week intervention and a 4-week follow-up with repeated measurements over time. The primary outcome is the cancer-related fatigue level over time, which will be measured by the functional assessment of chronic illness therapy-fatigue (FACIT-F) scale. To evaluate safety, the secondary outcome is the symptomatic adverse events, which will be assessed using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events in cancer clinical trials (PRO-CTCAE). Also, a subgroup analysis based on a decision tree-based machine learning algorithm will be employed for the clinical prediction of different agents in homogeneous subgroups. DISCUSSION: The findings of the 5-EPIFAT trial could be helpful to guide clinical decision-making, personalization treatment approach, design of future trials, as well as the development of CRF management guidelines. TRIAL REGISTRATION: IRCT.ir IRCT20150302021307N6. Registered on 13 May 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Miladinia M, Jahangiri M, White SJ, et al. 5-EPIFAT trial protocol: a multi-center, randomized, placebo-controlled trial of the efficacy of pharmacotherapy for fatigue using methylphenidate, bupropion, ginseng, and amantadine in advanced cancer patients on active treatment. Trials. 2024. PMID: 38570861. doi:10.1186/s13063-024-08078-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。